BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ratziu V. A critical review of endpoints for non-cirrhotic NASH therapeutic trials. Journal of Hepatology 2018;68:353-61. [DOI: 10.1016/j.jhep.2017.12.001] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 9.7] [Reference Citation Analysis]
Number Citing Articles
1 Farrell G, Schattenberg JM, Leclercq I, Yeh MM, Goldin R, Teoh N, Schuppan D. Mouse Models of Nonalcoholic Steatohepatitis: Toward Optimization of Their Relevance to Human Nonalcoholic Steatohepatitis. Hepatology 2019;69:2241-57. [PMID: 30372785 DOI: 10.1002/hep.30333] [Cited by in Crossref: 79] [Cited by in F6Publishing: 77] [Article Influence: 79.0] [Reference Citation Analysis]
2 Rinella ME, Tacke F, Sanyal AJ, Anstee QM; participants of the AASLD/EASL Workshop. Report on the AASLD/EASL Joint Workshop on Clinical Trial Endpoints in NAFLD. Hepatology. 2019;70:1424-1436. [PMID: 31287572 DOI: 10.1002/hep.30782] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 18.0] [Reference Citation Analysis]
3 Lv X, Dong Y, Hu L, Lu F, Zhou C, Qin S. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for the management of nonalcoholic fatty liver disease (NAFLD): A systematic review. Endocrinol Diabetes Metab 2020;3:e00163. [PMID: 32704576 DOI: 10.1002/edm2.163] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
4 De Rudder M, Bouzin C, Nachit M, Louvegny H, Vande Velde G, Julé Y, Leclercq IA. Automated computerized image analysis for the user-independent evaluation of disease severity in preclinical models of NAFLD/NASH. Lab Invest 2020;100:147-60. [PMID: 31506634 DOI: 10.1038/s41374-019-0315-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
5 Fang X, Du Z, Duan C, Zhan S, Wang T, Zhu M, Shi J, Meng J, Zhang X, Yang M, Zuo Y. Beinaglutide shows significantly beneficial effects in diabetes/obesity-induced nonalcoholic steatohepatitis in ob/ob mouse model. Life Sci 2021;270:118966. [PMID: 33482185 DOI: 10.1016/j.lfs.2020.118966] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
6 Mantovani A, Byrne C, Scorletti E, Mantzoros C, Targher G. Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials. Diabetes & Metabolism 2020;46:427-41. [DOI: 10.1016/j.diabet.2019.12.007] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 31.0] [Reference Citation Analysis]
7 Schattenberg JM. Reading the stars for hepatic fibrosis or how to predict the severity of liver disease in patients with NASH. Liver Int 2019;39:812-4. [PMID: 31020772 DOI: 10.1111/liv.13999] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
8 Huber Y, Pfirrmann D, Gebhardt I, Labenz C, Gehrke N, Straub BK, Ruckes C, Bantel H, Belda E, Clément K, Leeming DJ, Karsdal MA, Galle PR, Simon P, Schattenberg JM. Improvement of non-invasive markers of NAFLD from an individualised, web-based exercise program. Aliment Pharmacol Ther 2019;50:930-9. [PMID: 31342533 DOI: 10.1111/apt.15427] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 14.0] [Reference Citation Analysis]
9 European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu., Clinical Practice Guideline Panel., Chair:., EASL Governing Board representative:., Panel members:. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. J Hepatol 2021;75:659-89. [PMID: 34166721 DOI: 10.1016/j.jhep.2021.05.025] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 16.0] [Reference Citation Analysis]
10 Stefan N, Häring H, Cusi K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. The Lancet Diabetes & Endocrinology 2019;7:313-24. [DOI: 10.1016/s2213-8587(18)30154-2] [Cited by in Crossref: 220] [Cited by in F6Publishing: 115] [Article Influence: 110.0] [Reference Citation Analysis]
11 Marti-Aguado D, Rodríguez-Ortega A, Mestre-Alagarda C, Bauza M, Valero-Pérez E, Alfaro-Cervello C, Benlloch S, Pérez-Rojas J, Ferrández A, Alemany-Monraval P, Escudero-García D, Monton C, Aguilera V, Alberich-Bayarri Á, Serra MÁ, Marti-Bonmati L. Digital pathology: accurate technique for quantitative assessment of histological features in metabolic-associated fatty liver disease. Aliment Pharmacol Ther 2021;53:160-71. [PMID: 32981113 DOI: 10.1111/apt.16100] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Fiorucci S, Biagioli M, Sepe V, Zampella A, Distrutti E. Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH). Expert Opin Investig Drugs 2020;29:623-32. [PMID: 32552182 DOI: 10.1080/13543784.2020.1763302] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
13 Petroni ML, Brodosi L, Bugianesi E, Marchesini G. Management of non-alcoholic fatty liver disease.BMJ. 2021;372:m4747. [PMID: 33461969 DOI: 10.1136/bmj.m4747] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
14 Labenz C, Prochaska JH, Huber Y, Nagel M, Straub BK, Wild P, Galle PR, Schattenberg JM. Cardiovascular Risk Categories in Patients With Nonalcoholic Fatty Liver Disease and the Role of Low-Density Lipoprotein Cholesterol. Hepatol Commun 2019;3:1472-81. [PMID: 31701071 DOI: 10.1002/hep4.1428] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
15 Sun YM, Chen SY, You H. Regression of liver fibrosis: evidence and challenges. Chin Med J (Engl) 2020;133:1696-702. [PMID: 32568866 DOI: 10.1097/CM9.0000000000000835] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
16 Rowe IA. Histological Endpoints for Nonalcoholic Steatohepatitis Trials: Lights and Shadows. Semin Liver Dis 2020;40:339-45. [PMID: 32906165 DOI: 10.1055/s-0040-1709491] [Reference Citation Analysis]
17 Azevedo VZ, Dall'Alba V. Fructose intake is not associated to the risk of hepatic fibrosis in patients with Non-Alcoholic Fatty Liver Disease (NAFLD). Clin Nutr 2021;40:4275-83. [PMID: 33551215 DOI: 10.1016/j.clnu.2021.01.022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Stefan N. [New aspects of nonalcoholic steatohepatitis]. Internist (Berl) 2019;60:128-32. [PMID: 30645665 DOI: 10.1007/s00108-018-0550-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Black D, Brockbank S, Cruwys S, Goldenstein K, Hein P, Humphries B. The future R&D landscape in non-alcoholic steatohepatitis (NASH). Drug Discovery Today 2019;24:560-6. [DOI: 10.1016/j.drudis.2018.09.020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
20 George J, Anstee Q, Ratziu V, Sanyal A. NAFLD: The evolving landscape. J Hepatol 2018;68:227-9. [PMID: 29223512 DOI: 10.1016/j.jhep.2017.11.016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
21 Chikada H, Ida K, Nishikawa Y, Inagaki Y, Kamiya A. Liver-specific knockout of B cell lymphoma 6 suppresses progression of non-alcoholic steatohepatitis in mice. Sci Rep 2020;10:9704. [PMID: 32546802 DOI: 10.1038/s41598-020-66539-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Banerjee R, Kelly M, Wilman H, Wright T, Neubauer S. Imaging endpoints for non-alcoholic steatohepatitis (NASH) therapeutic trials: A growing role for multiparametric MRI? Journal of Hepatology 2018;69:755-6. [DOI: 10.1016/j.jhep.2018.04.022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
23 Rinella ME, Tacke F, Sanyal AJ, Anstee QM. Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD. Journal of Hepatology 2019;71:823-33. [DOI: 10.1016/j.jhep.2019.04.019] [Cited by in Crossref: 45] [Cited by in F6Publishing: 48] [Article Influence: 22.5] [Reference Citation Analysis]
24 Ipsen DH, Lykkesfeldt J, Tveden-Nyborg P. Animal Models of Fibrosis in Nonalcoholic Steatohepatitis: Do They Reflect Human Disease? Adv Nutr 2020;11:1696-711. [PMID: 33191435 DOI: 10.1093/advances/nmaa081] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
25 Pantano L, Agyapong G, Shen Y, Zhuo Z, Fernandez-Albert F, Rust W, Knebel D, Hill J, Boustany-Kari CM, Doerner JF, Rippmann JF, Chung RT, Ho Sui SJ, Simon E, Corey KE. Molecular characterization and cell type composition deconvolution of fibrosis in NAFLD. Sci Rep 2021;11:18045. [PMID: 34508113 DOI: 10.1038/s41598-021-96966-5] [Reference Citation Analysis]
26 Drenth JP, Schattenberg JM. The nonalcoholic steatohepatitis (NASH) drug development graveyard: established hurdles and planning for future success. Expert Opinion on Investigational Drugs 2020;29:1365-75. [DOI: 10.1080/13543784.2020.1839888] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
27 Ratziu V, Rinella ME, Neuschwander-Tetri BA, Lawitz E, Denham D, Kayali Z, Sheikh A, Kowdley KV, Desta T, Elkhashab M, DeGrauw J, Goodwin B, Ahmad A, Adda N. EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study. J Hepatol 2021:S0168-8278(21)02155-3. [PMID: 34740705 DOI: 10.1016/j.jhep.2021.10.018] [Reference Citation Analysis]
28 Yoo JJ, Kim W, Kim MY, Jun DW, Kim SG, Yeon JE, Lee JW, Cho YK, Park SH, Sohn JH; the Korean Association for the Study of the Liver (KASL)-Korea Nonalcoholic fatty liver Study Group (KNSG). Recent research trends and updates on nonalcoholic fatty liver disease. Clin Mol Hepatol 2019;25:1-11. [PMID: 30086613 DOI: 10.3350/cmh.2018.0037] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 11.7] [Reference Citation Analysis]
29 Masoodi M, Gastaldelli A, Hyötyläinen T, Arretxe E, Alonso C, Gaggini M, Brosnan J, Anstee QM, Millet O, Ortiz P, Mato JM, Dufour JF, Orešič M. Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests. Nat Rev Gastroenterol Hepatol 2021. [PMID: 34508238 DOI: 10.1038/s41575-021-00502-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Adams LA. End-points for drug treatment in NASH. Hepatol Int 2019;13:253-8. [DOI: 10.1007/s12072-019-09935-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
31 Milaciu MV, Ciumărnean L, Matei DM, Vesa ȘC, Sabin O, Bocșan IC, Pop RM, Negrean V, Buzoianu AD, Acalovschi M. Cytokines, paraoxonase-1, periostin and non-invasive liver fibrosis scores in patients with non-alcoholic fatty liver disease and persistently elevated aminotransferases: A pilot study. Exp Ther Med 2021;21:533. [PMID: 33815606 DOI: 10.3892/etm.2021.9965] [Reference Citation Analysis]
32 Arrese M, Barrera F, Triantafilo N, Arab JP. Concurrent nonalcoholic fatty liver disease and type 2 diabetes: diagnostic and therapeutic considerations. Expert Review of Gastroenterology & Hepatology 2019;13:849-66. [DOI: 10.1080/17474124.2019.1649981] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 9.0] [Reference Citation Analysis]
33 Gim JA, Bang SM, Lee YS, Lee Y, Yim SY, Jung YK, Kim H, Kim BH, Kim JH, Seo YS, Yim HJ, Yeon JE, Um SH, Byun KS. Evaluation of the severity of nonalcoholic fatty liver disease through analysis of serum exosomal miRNA expression. PLoS One 2021;16:e0255822. [PMID: 34358264 DOI: 10.1371/journal.pone.0255822] [Reference Citation Analysis]